Energex asks for FDA OK to offer therapy for swine flu

Energex Systems of the USA says that it has notified the Food and Drug Administration of its interest in applying for an Emergency Use Approval  that would permit the company to offer its HemoModulation therapy for  the treatment of type A, H1N1, otherwise known as swine flu.  HemoModulation therapy was shown to inactivate the virus in mice. This  same treatment has been under review by the FDA and is in human clinical  trials for hepatitis C and HIV.

HemoModulation therapy is a process using UVC energy to inactivate the  particular strain of virus that the patient is infected with, and  returning to the body. The hypothesis is that UV inactivated virus will  serve as an autologous vaccine and boost the immune system of the  patient against their particular strain of virus. The process takes  around 30 minutes and can be administered in an office, laboratory or  any other health care facility. An animation of the procedure can be  viewed at http://www.energexsystems.com/hemomod.htm.

In animal studies, says Thomas Petrie, the company's R&D director, the  therapy produced discernable and substantial improvement in both  clinical disease and pulmonary function in mice infected with the H1N1  virus. Minimal clinical illness was observed up to nine days post  infection for those animals that were treated. In contrast, the  sham-treated animals developed severe illness by day six that did not  significantly resolve through the 13-day course of the study. As  measured by pulmonary lung function testing, infected animals that were  treated with HemoModulation exhibited a significantly-greater ability to  breathe relative to their sham-treated counterparts and pathological  examination of lungs clearly indicated that treatment significantly  inhibited virus-induced inflammation resulting in airways that were for  the most part, clear of inflammatory cells and cellular debris.